Unichem Pharmaceuticals (USA), Inc. announced today the receipt of approval for ANDA207429 to manufacture the oral tablets of Sotalol Hydrochloride, a beta-blocker traditionally viewed as a commodity therapy but with a complex safety profile. The supply of this FDA-approved generic is poised to intensify competition within the antihypertensive and antiarrhythmic markets, driving pricing pressure despite the medication's medically_critical nature46-like monitoring requirements.